Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evelien J M Kuip

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|April 29, 2026
[The blind spot in oncological care; disease scenarios as a foundation for careful decision-making]Evelien J M Kuip, Eric C T Geijteman, Hans M Westgeest
BMJ (Clinical Research Ed.)|March 1, 2024
Illness trajectories of incurable solid cancersEric C T Geijteman, Evelien J M Kuip, Jannie Oskam, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 29, 2017
Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasmaPeter de Bruijn, Evelien J M Kuip, Mei-Ho Lam, et al.
Plos One|April 7, 2026
Communication patterns in decision-making consultations between patients with advanced cancer and medical oncologists: A qualitative observational studyDaisy J M Ermers, Yvonne Engels, Henk J Schers, et al.
Journal of Pain and Symptom Management|November 28, 2017
Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate CancerHarm Westdorp, Evelien J M Kuip, Inge M van Oort, et al.
British Journal of Clinical Pharmacology|September 14, 2016
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patientsEvelien J M Kuip, Maarten L Zandvliet, Stijn L W Koolen, et al.
JCO Clinical Cancer Informatics|June 30, 2025
Machine Learning-Based Prediction of Clinical Outcomes in Patients With Cancer Receiving Systemic Treatment Using Step Count Data Measured With SmartphonesCalvin G Brouwer, Branca M Bartelet, Joeri A J Douma, et al.
Palliative & Supportive Care|February 16, 2024
Are specialist-provided end-of-life scenarios key to initiation of advance care planning in primary care? A mixed-methods studySophie W Poelman, Daisy J M Ermers, Henk J Schers, et al.
European Journal of Clinical Pharmacology|January 15, 2016
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patientsAstrid W Oosten, João A Abrantes, Siv Jönsson, et al.
Oncotarget|May 3, 2018
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanylEvelien J M Kuip, Wendy H Oldenmenger, Martine F Visser-Thijs, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Nederlands Tijdschrift Voor Geneeskunde|April 29, 2026
[The blind spot in oncological care; disease scenarios as a foundation for careful decision-making]Evelien J M Kuip, Eric C T Geijteman, Hans M Westgeest
BMJ (Clinical Research Ed.)|March 1, 2024
Illness trajectories of incurable solid cancersEric C T Geijteman, Evelien J M Kuip, Jannie Oskam, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 29, 2017
Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasmaPeter de Bruijn, Evelien J M Kuip, Mei-Ho Lam, et al.
Plos One|April 7, 2026
Communication patterns in decision-making consultations between patients with advanced cancer and medical oncologists: A qualitative observational studyDaisy J M Ermers, Yvonne Engels, Henk J Schers, et al.
Journal of Pain and Symptom Management|November 28, 2017
Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate CancerHarm Westdorp, Evelien J M Kuip, Inge M van Oort, et al.
British Journal of Clinical Pharmacology|September 14, 2016
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patientsEvelien J M Kuip, Maarten L Zandvliet, Stijn L W Koolen, et al.
JCO Clinical Cancer Informatics|June 30, 2025
Machine Learning-Based Prediction of Clinical Outcomes in Patients With Cancer Receiving Systemic Treatment Using Step Count Data Measured With SmartphonesCalvin G Brouwer, Branca M Bartelet, Joeri A J Douma, et al.
Palliative & Supportive Care|February 16, 2024
Are specialist-provided end-of-life scenarios key to initiation of advance care planning in primary care? A mixed-methods studySophie W Poelman, Daisy J M Ermers, Henk J Schers, et al.
European Journal of Clinical Pharmacology|January 15, 2016
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patientsAstrid W Oosten, João A Abrantes, Siv Jönsson, et al.
Oncotarget|May 3, 2018
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanylEvelien J M Kuip, Wendy H Oldenmenger, Martine F Visser-Thijs, et al.
Pageof 3